Clinical Trial Update: Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Dependence
• Opioid Use Disorder
• Opioid Withdrawal Syndrome

Drugs mentioned

• LOFEXIDINE (LOFEXIDINE)

Snippet

Sponsor: USWM, LLC (dba US WorldMeds) | Conditions: Substance Withdrawal Syndrome, Opiate Addiction | Phase 1 | Status: COMPLETED